CD8A and cancer: Therefore, applying immunizations with nonreplicable (MMC-treated or irradiated) cancer cells of surgically-resected their own CRC in combination with an effective adjuvant to potently activate the cancer-specific CD8+ cytotoxic T cells would be a valuable approach to activate the protective immunity specifically against their own cancer cells and prevent recurrence of their CRC.